Learn More
R&D Systems™ Recombinant Human CD25/IL-2R alpha Fc Chimera Protein, CF
Extensive quality control produces industry leading bioactivity and lot-to-lot consistency that instills confidence in results and ensures reproducibility. Applications: Bioactivity
Supplier: R&D Systems™ 1020RL050
Description
The Recombinant Human CD25/IL-2 R alpha Fc Chimera Protein is derived from NS0. The Recombinant Human CD25/IL-2 R alpha Fc Chimera Protein has been validated for the following applications: Bioactivity.Specifications
Lyophilized from a 0.2μm filtered solution in PBS. | |
48.3 kDa (monomer) | |
50μg | |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70° C as supplied. 1 month, 2 to 8° C under sterile conditions after reconstitution. 3 months, -20 to -70° C under sterile conditions after reconstitution. | |
Unconjugated | |
95%, by SDS-PAGE under reducing conditions and visualized by silver stain. |
3559 | |
CD25/IL-2R alpha | |
Mouse myeloma cell line,NS0-derived human CD25/IL-2 R alpha protein, (N-terminus) Human CD25/IL-2 R alpha (Glu22-Cys213) Accession &Num; Q5W007 IEGRMD Human IgG1 (Pro100-Lys330) (C-terminus) | |
Disulfide-linked homodimer | |
Recombinant |
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.